236 related articles for article (PubMed ID: 31544864)
1. A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody-Drug Conjugates.
Verkade JMM; Wijdeven MA; Van Geel R; Janssen BMG; Van Berkel SS; Van Delft FL
Antibodies (Basel); 2018 Feb; 7(1):. PubMed ID: 31544864
[TBL] [Abstract][Full Text] [Related]
2. Enzymatic glycan remodeling-metal free click (GlycoConnect™) provides homogenous antibody-drug conjugates with improved stability and therapeutic index without sequence engineering.
Wijdeven MA; van Geel R; Hoogenboom JH; Verkade JMM; Janssen BMG; Hurkmans I; de Bever L; van Berkel SS; van Delft FL
MAbs; 2022; 14(1):2078466. PubMed ID: 35634725
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
[TBL] [Abstract][Full Text] [Related]
4. Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody-Drug Conjugates.
Matsuda Y; Seki T; Yamada K; Ooba Y; Takahashi K; Fujii T; Kawaguchi S; Narita T; Nakayama A; Kitahara Y; Mendelsohn BA; Okuzumi T
Mol Pharm; 2021 Nov; 18(11):4058-4066. PubMed ID: 34579528
[TBL] [Abstract][Full Text] [Related]
5. Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates.
van Geel R; Wijdeven MA; Heesbeen R; Verkade JM; Wasiel AA; van Berkel SS; van Delft FL
Bioconjug Chem; 2015 Nov; 26(11):2233-42. PubMed ID: 26061183
[TBL] [Abstract][Full Text] [Related]
6. Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates.
Puthenveetil S; Musto S; Loganzo F; Tumey LN; O'Donnell CJ; Graziani E
Bioconjug Chem; 2016 Apr; 27(4):1030-9. PubMed ID: 26942771
[TBL] [Abstract][Full Text] [Related]
7. Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy
Su D; Zhang D
Front Pharmacol; 2021; 12():687926. PubMed ID: 34248637
[TBL] [Abstract][Full Text] [Related]
8. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
Tsuchikama K
Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
[TBL] [Abstract][Full Text] [Related]
9. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates.
Frigerio M; Kyle AF
Curr Top Med Chem; 2017; 17(32):3393-3424. PubMed ID: 29357801
[TBL] [Abstract][Full Text] [Related]
10. Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform.
Dokter W; Ubink R; van der Lee M; van der Vleuten M; van Achterberg T; Jacobs D; Loosveld E; van den Dobbelsteen D; Egging D; Mattaar E; Groothuis P; Beusker P; Coumans R; Elgersma R; Menge W; Joosten J; Spijker H; Huijbregts T; de Groot V; Eppink M; de Roo G; Verheijden G; Timmers M
Mol Cancer Ther; 2014 Nov; 13(11):2618-29. PubMed ID: 25189543
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications.
Dan N; Setua S; Kashyap VK; Khan S; Jaggi M; Yallapu MM; Chauhan SC
Pharmaceuticals (Basel); 2018 Apr; 11(2):. PubMed ID: 29642542
[TBL] [Abstract][Full Text] [Related]
12. State-of-the-Art Native Mass Spectrometry and Ion Mobility Methods to Monitor Homogeneous Site-Specific Antibody-Drug Conjugates Synthesis.
Deslignière E; Ehkirch A; Duivelshof BL; Toftevall H; Sjögren J; Guillarme D; D'Atri V; Beck A; Hernandez-Alba O; Cianférani S
Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34073805
[TBL] [Abstract][Full Text] [Related]
13. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
14. Generation of DAR1 Antibody-Drug Conjugates for Ultrapotent Payloads Using Tailored GlycoConnect Technology.
de Bever L; Popal S; van Schaik J; Rubahamya B; van Delft FL; Thurber GM; van Berkel SS
Bioconjug Chem; 2023 Mar; 34(3):538-548. PubMed ID: 36857521
[TBL] [Abstract][Full Text] [Related]
15. Joint Disposition Properties and Comprehensive Pharmacokinetic Characterization of Antibody-Drug Conjugates.
Liao KH; Williams JH; Palani S; Yin D; Meng X
AAPS J; 2022 Jun; 24(4):73. PubMed ID: 35688991
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Two Chemoenzymatic Glycan Remodeling Approaches to Generate Site-Specific Antibody-Drug Conjugates.
Yang Q; Chen H; Ou C; Zheng Z; Zhang X; Liu Y; Zong G; Wang LX
Antibodies (Basel); 2023 Nov; 12(4):. PubMed ID: 37987249
[TBL] [Abstract][Full Text] [Related]
17. Introduction to Antibody-Drug Conjugates.
Pettinato MC
Antibodies (Basel); 2021 Oct; 10(4):. PubMed ID: 34842621
[TBL] [Abstract][Full Text] [Related]
18. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
[TBL] [Abstract][Full Text] [Related]
19. Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility.
Satomaa T; Pynnönen H; Vilkman A; Kotiranta T; Pitkänen V; Heiskanen A; Herpers B; Price LS; Helin J; Saarinen J
Antibodies (Basel); 2018 Mar; 7(2):. PubMed ID: 31544867
[TBL] [Abstract][Full Text] [Related]
20. Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation.
Matsuda Y; Malinao MC; Robles V; Song J; Yamada K; Mendelsohn BA
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Mar; 1140():121981. PubMed ID: 32036254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
